| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Keratitis, Herpetic | 7 | 2025 | 9 | 2.890 |
Why?
|
| Cornea | 9 | 2021 | 54 | 2.180 |
Why?
|
| Corneal Diseases | 7 | 2021 | 29 | 2.000 |
Why?
|
| Visual Acuity | 12 | 2022 | 195 | 1.960 |
Why?
|
| Dry Eye Syndromes | 2 | 2022 | 5 | 1.450 |
Why?
|
| Acanthamoeba Keratitis | 2 | 2021 | 5 | 1.290 |
Why?
|
| Anti-Bacterial Agents | 6 | 2024 | 833 | 1.180 |
Why?
|
| Simplexvirus | 4 | 2017 | 66 | 1.150 |
Why?
|
| Keratitis | 2 | 2019 | 12 | 1.110 |
Why?
|
| Epithelium, Corneal | 4 | 2025 | 13 | 1.060 |
Why?
|
| Corneal Dystrophies, Hereditary | 2 | 2019 | 4 | 1.020 |
Why?
|
| Ophthalmologic Surgical Procedures | 5 | 2022 | 20 | 1.020 |
Why?
|
| Conjunctiva | 2 | 2018 | 14 | 1.000 |
Why?
|
| Corneal Stroma | 4 | 2021 | 10 | 0.960 |
Why?
|
| Eye Infections, Viral | 1 | 2025 | 2 | 0.920 |
Why?
|
| Glaucoma | 1 | 2025 | 35 | 0.880 |
Why?
|
| Keratoplasty, Penetrating | 5 | 2019 | 7 | 0.840 |
Why?
|
| Acanthamoeba | 2 | 2021 | 15 | 0.820 |
Why?
|
| Endophthalmitis | 1 | 2024 | 18 | 0.810 |
Why?
|
| Phosphorylcholine | 2 | 2021 | 22 | 0.780 |
Why?
|
| Ophthalmic Solutions | 3 | 2021 | 14 | 0.750 |
Why?
|
| Eye Infections, Parasitic | 2 | 2019 | 3 | 0.740 |
Why?
|
| Lubricant Eye Drops | 1 | 2022 | 1 | 0.720 |
Why?
|
| Contact Lenses, Hydrophilic | 2 | 2019 | 2 | 0.720 |
Why?
|
| Cataract Extraction | 3 | 2021 | 31 | 0.720 |
Why?
|
| Eye Infections, Bacterial | 2 | 2019 | 11 | 0.720 |
Why?
|
| Graves Ophthalmopathy | 1 | 2020 | 3 | 0.660 |
Why?
|
| Scleritis | 1 | 2020 | 4 | 0.660 |
Why?
|
| Corneal Edema | 3 | 2021 | 5 | 0.650 |
Why?
|
| Retinal Detachment | 1 | 2020 | 59 | 0.630 |
Why?
|
| Micrococcaceae | 1 | 2019 | 2 | 0.610 |
Why?
|
| Acyclovir | 2 | 2017 | 35 | 0.600 |
Why?
|
| Humans | 54 | 2025 | 93138 | 0.600 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2019 | 52 | 0.590 |
Why?
|
| Keratoconus | 2 | 2021 | 7 | 0.580 |
Why?
|
| Keratoconjunctivitis | 1 | 2018 | 2 | 0.570 |
Why?
|
| Linezolid | 1 | 2018 | 4 | 0.570 |
Why?
|
| Eye Infections, Fungal | 2 | 2016 | 12 | 0.570 |
Why?
|
| Mucormycosis | 2 | 2016 | 15 | 0.560 |
Why?
|
| Pseudolymphoma | 1 | 2018 | 7 | 0.560 |
Why?
|
| Conjunctivitis, Allergic | 1 | 2018 | 9 | 0.560 |
Why?
|
| Biofilms | 1 | 2018 | 50 | 0.550 |
Why?
|
| Vancomycin | 1 | 2018 | 75 | 0.540 |
Why?
|
| Prosthesis-Related Infections | 1 | 2018 | 59 | 0.540 |
Why?
|
| Prostheses and Implants | 1 | 2018 | 121 | 0.530 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2018 | 83 | 0.530 |
Why?
|
| Herpes Zoster Ophthalmicus | 1 | 2017 | 3 | 0.530 |
Why?
|
| Cicatrix | 1 | 2017 | 74 | 0.500 |
Why?
|
| Anthozoa | 1 | 2016 | 14 | 0.500 |
Why?
|
| Acrylamides | 1 | 2016 | 34 | 0.490 |
Why?
|
| Multiple Myeloma | 3 | 2025 | 336 | 0.460 |
Why?
|
| Ocular Hypotension | 1 | 2015 | 4 | 0.460 |
Why?
|
| Orbit Evisceration | 1 | 2015 | 1 | 0.450 |
Why?
|
| Corneal Transplantation | 3 | 2021 | 7 | 0.450 |
Why?
|
| Orbital Cellulitis | 1 | 2015 | 4 | 0.450 |
Why?
|
| Eye Hemorrhage | 1 | 2015 | 1 | 0.440 |
Why?
|
| Retinal Vasculitis | 1 | 2015 | 4 | 0.440 |
Why?
|
| Astigmatism | 3 | 2021 | 5 | 0.440 |
Why?
|
| Aspergillosis | 1 | 2015 | 39 | 0.440 |
Why?
|
| Trypan Blue | 1 | 2014 | 3 | 0.440 |
Why?
|
| Coloring Agents | 1 | 2014 | 65 | 0.430 |
Why?
|
| Antiviral Agents | 4 | 2025 | 364 | 0.420 |
Why?
|
| Eye Diseases | 3 | 2025 | 56 | 0.410 |
Why?
|
| Immunoconjugates | 2 | 2025 | 129 | 0.410 |
Why?
|
| Cataract | 3 | 2023 | 87 | 0.400 |
Why?
|
| Virus Internalization | 2 | 2010 | 45 | 0.390 |
Why?
|
| Intraoperative Complications | 1 | 2014 | 191 | 0.390 |
Why?
|
| Autoimmune Diseases | 1 | 2015 | 255 | 0.370 |
Why?
|
| Steroids | 3 | 2024 | 166 | 0.360 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2024 | 249 | 0.340 |
Why?
|
| Eye | 2 | 2018 | 108 | 0.340 |
Why?
|
| Intraocular Pressure | 2 | 2025 | 61 | 0.340 |
Why?
|
| Postoperative Complications | 3 | 2023 | 2552 | 0.340 |
Why?
|
| Preservatives, Pharmaceutical | 2 | 2022 | 9 | 0.320 |
Why?
|
| Optic Nerve Diseases | 2 | 2021 | 16 | 0.310 |
Why?
|
| Endothelium, Corneal | 2 | 2020 | 19 | 0.310 |
Why?
|
| Strabismus | 2 | 2020 | 9 | 0.300 |
Why?
|
| Oculomotor Muscles | 2 | 2020 | 27 | 0.300 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2025 | 1000 | 0.300 |
Why?
|
| Retrospective Studies | 11 | 2023 | 10132 | 0.280 |
Why?
|
| Middle Aged | 13 | 2025 | 27539 | 0.280 |
Why?
|
| Herpesvirus 1, Human | 3 | 2017 | 210 | 0.260 |
Why?
|
| Female | 13 | 2025 | 48547 | 0.250 |
Why?
|
| Male | 19 | 2025 | 44360 | 0.250 |
Why?
|
| Tears | 2 | 2025 | 7 | 0.240 |
Why?
|
| Gonioscopy | 1 | 2025 | 7 | 0.230 |
Why?
|
| Trabecular Meshwork | 1 | 2025 | 6 | 0.230 |
Why?
|
| Diagnosis, Differential | 4 | 2018 | 1519 | 0.230 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2021 | 422 | 0.230 |
Why?
|
| Trabeculectomy | 1 | 2025 | 7 | 0.230 |
Why?
|
| Glaucoma Drainage Implants | 1 | 2025 | 11 | 0.230 |
Why?
|
| Blindness | 2 | 2018 | 39 | 0.220 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2025 | 95 | 0.210 |
Why?
|
| Chronic Disease | 2 | 2018 | 941 | 0.200 |
Why?
|
| Vitreous Body | 1 | 2024 | 52 | 0.200 |
Why?
|
| Tomography, Optical Coherence | 3 | 2021 | 123 | 0.200 |
Why?
|
| Macular Edema | 1 | 2023 | 41 | 0.200 |
Why?
|
| Aged | 8 | 2025 | 20398 | 0.190 |
Why?
|
| Slit Lamp Microscopy | 2 | 2019 | 4 | 0.190 |
Why?
|
| Play and Playthings | 1 | 2022 | 7 | 0.180 |
Why?
|
| Eye Injuries | 1 | 2022 | 15 | 0.180 |
Why?
|
| Orbit | 2 | 2019 | 36 | 0.180 |
Why?
|
| Eye Banks | 1 | 2021 | 3 | 0.170 |
Why?
|
| Disease Management | 2 | 2021 | 357 | 0.170 |
Why?
|
| Oxidative Stress | 2 | 2023 | 467 | 0.170 |
Why?
|
| Infant, Newborn | 2 | 2025 | 2427 | 0.170 |
Why?
|
| Nerve Growth Factor | 1 | 2021 | 18 | 0.170 |
Why?
|
| Bandages | 2 | 2018 | 42 | 0.170 |
Why?
|
| Proteomics | 1 | 2023 | 261 | 0.170 |
Why?
|
| Retinal Perforations | 1 | 2020 | 13 | 0.170 |
Why?
|
| Tissue Preservation | 1 | 2020 | 15 | 0.160 |
Why?
|
| Vitrectomy | 1 | 2020 | 46 | 0.160 |
Why?
|
| Glucocorticoids | 2 | 2023 | 360 | 0.160 |
Why?
|
| DNA, Protozoan | 1 | 2019 | 15 | 0.160 |
Why?
|
| Lymphoma | 1 | 2021 | 247 | 0.160 |
Why?
|
| Antiprotozoal Agents | 1 | 2019 | 30 | 0.150 |
Why?
|
| Hydrocodone | 1 | 2019 | 8 | 0.150 |
Why?
|
| Keloid | 1 | 2019 | 8 | 0.150 |
Why?
|
| Eye Injuries, Penetrating | 1 | 2019 | 6 | 0.150 |
Why?
|
| Adult | 8 | 2023 | 27850 | 0.150 |
Why?
|
| Orbital Implants | 1 | 2019 | 3 | 0.150 |
Why?
|
| Pilot Projects | 2 | 2019 | 913 | 0.140 |
Why?
|
| Microscopy, Confocal | 1 | 2019 | 281 | 0.140 |
Why?
|
| Acetaminophen | 1 | 2019 | 61 | 0.140 |
Why?
|
| Fuchs' Endothelial Dystrophy | 1 | 2019 | 11 | 0.140 |
Why?
|
| Paranasal Sinus Diseases | 1 | 2019 | 19 | 0.140 |
Why?
|
| Optic Nerve | 2 | 2021 | 35 | 0.140 |
Why?
|
| Benzalkonium Compounds | 1 | 2018 | 1 | 0.140 |
Why?
|
| Polyps | 1 | 2019 | 26 | 0.140 |
Why?
|
| Loteprednol Etabonate | 1 | 2018 | 1 | 0.140 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 223 | 0.140 |
Why?
|
| Administration, Ophthalmic | 1 | 2018 | 8 | 0.140 |
Why?
|
| Antigens, CD20 | 1 | 2018 | 33 | 0.140 |
Why?
|
| Prednisolone | 1 | 2018 | 36 | 0.140 |
Why?
|
| Orbital Fractures | 1 | 2018 | 13 | 0.140 |
Why?
|
| Administration, Oral | 1 | 2019 | 655 | 0.140 |
Why?
|
| Anti-Allergic Agents | 1 | 2018 | 38 | 0.140 |
Why?
|
| Diplopia | 1 | 2018 | 13 | 0.140 |
Why?
|
| Incidence | 4 | 2019 | 1697 | 0.140 |
Why?
|
| Anesthetics | 1 | 2018 | 51 | 0.140 |
Why?
|
| Immunoenzyme Techniques | 1 | 2018 | 291 | 0.140 |
Why?
|
| Optic Disk | 1 | 2018 | 14 | 0.140 |
Why?
|
| Corneal Topography | 1 | 2017 | 8 | 0.130 |
Why?
|
| Antifungal Agents | 2 | 2016 | 122 | 0.130 |
Why?
|
| Conjunctival Neoplasms | 1 | 2017 | 2 | 0.130 |
Why?
|
| Contact Lenses | 1 | 2017 | 3 | 0.130 |
Why?
|
| Photorefractive Keratectomy | 1 | 2017 | 3 | 0.130 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2017 | 6 | 0.130 |
Why?
|
| Eye Movements | 1 | 2018 | 119 | 0.130 |
Why?
|
| Keratitis, Dendritic | 1 | 2017 | 2 | 0.130 |
Why?
|
| Surgeons | 1 | 2021 | 292 | 0.130 |
Why?
|
| Toxoplasmosis, Ocular | 1 | 2016 | 17 | 0.130 |
Why?
|
| Cnidarian Venoms | 1 | 2016 | 19 | 0.120 |
Why?
|
| Pain, Postoperative | 1 | 2019 | 274 | 0.120 |
Why?
|
| Refractive Surgical Procedures | 1 | 2016 | 1 | 0.120 |
Why?
|
| Eye Infections | 1 | 2016 | 3 | 0.120 |
Why?
|
| Explosions | 1 | 2016 | 7 | 0.120 |
Why?
|
| Eye Burns | 1 | 2016 | 6 | 0.120 |
Why?
|
| Corneal Injuries | 1 | 2016 | 8 | 0.120 |
Why?
|
| Blast Injuries | 1 | 2016 | 10 | 0.120 |
Why?
|
| Sclera | 1 | 2016 | 12 | 0.120 |
Why?
|
| Antihypertensive Agents | 1 | 2018 | 256 | 0.120 |
Why?
|
| Bone Marrow Transplantation | 1 | 2017 | 281 | 0.120 |
Why?
|
| Herpes Simplex | 1 | 2017 | 78 | 0.120 |
Why?
|
| Rhizopus | 1 | 2016 | 2 | 0.120 |
Why?
|
| Corneal Ulcer | 1 | 2016 | 5 | 0.120 |
Why?
|
| Cysticercosis | 1 | 2016 | 2 | 0.120 |
Why?
|
| Lacerations | 1 | 2016 | 29 | 0.120 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 127 | 0.120 |
Why?
|
| Eye Pain | 1 | 2015 | 4 | 0.120 |
Why?
|
| Forecasting | 1 | 2016 | 288 | 0.120 |
Why?
|
| Dilatation, Pathologic | 1 | 2015 | 47 | 0.110 |
Why?
|
| Cocaine-Related Disorders | 1 | 2016 | 39 | 0.110 |
Why?
|
| Pandemics | 1 | 2021 | 873 | 0.110 |
Why?
|
| Global Health | 2 | 2019 | 207 | 0.110 |
Why?
|
| Conjunctival Diseases | 1 | 2015 | 6 | 0.110 |
Why?
|
| Vision Disorders | 1 | 2015 | 71 | 0.110 |
Why?
|
| Graft vs Host Disease | 1 | 2017 | 365 | 0.110 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2016 | 72 | 0.110 |
Why?
|
| Tuberculosis, Ocular | 1 | 2015 | 9 | 0.110 |
Why?
|
| Endoscopy | 1 | 2019 | 366 | 0.110 |
Why?
|
| Retinal Diseases | 1 | 2016 | 80 | 0.110 |
Why?
|
| Lens Capsule, Crystalline | 1 | 2014 | 11 | 0.110 |
Why?
|
| Lens Implantation, Intraocular | 1 | 2014 | 23 | 0.110 |
Why?
|
| Granuloma | 1 | 2015 | 64 | 0.110 |
Why?
|
| Biopsy | 1 | 2018 | 1172 | 0.110 |
Why?
|
| Antibodies, Antinuclear | 1 | 2015 | 94 | 0.110 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 515 | 0.110 |
Why?
|
| Staining and Labeling | 1 | 2014 | 155 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 619 | 0.100 |
Why?
|
| Nectins | 2 | 2010 | 6 | 0.100 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 2013 | 4 | 0.100 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2013 | 12 | 0.100 |
Why?
|
| Papilledema | 1 | 2013 | 4 | 0.100 |
Why?
|
| Optic Chiasm | 1 | 2013 | 16 | 0.100 |
Why?
|
| B-Lymphocytes | 1 | 2018 | 703 | 0.100 |
Why?
|
| Microbiota | 1 | 2018 | 431 | 0.100 |
Why?
|
| Cell Adhesion Molecules | 2 | 2010 | 172 | 0.090 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2015 | 208 | 0.090 |
Why?
|
| Aged, 80 and over | 3 | 2025 | 7039 | 0.090 |
Why?
|
| Prevalence | 2 | 2016 | 1318 | 0.090 |
Why?
|
| Drug Resistance, Viral | 1 | 2012 | 37 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2019 | 2562 | 0.090 |
Why?
|
| Risk Factors | 1 | 2022 | 5901 | 0.090 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 1276 | 0.080 |
Why?
|
| Population Surveillance | 1 | 2012 | 212 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 1073 | 0.080 |
Why?
|
| Receptors, Virus | 1 | 2010 | 73 | 0.080 |
Why?
|
| Receptors, Tumor Necrosis Factor, Member 14 | 1 | 2010 | 7 | 0.080 |
Why?
|
| Clinical Competence | 1 | 2016 | 810 | 0.080 |
Why?
|
| Virus Attachment | 1 | 2010 | 6 | 0.080 |
Why?
|
| Sulfotransferases | 1 | 2010 | 15 | 0.080 |
Why?
|
| Heparitin Sulfate | 1 | 2010 | 25 | 0.080 |
Why?
|
| Pseudopodia | 1 | 2010 | 36 | 0.080 |
Why?
|
| Animals | 5 | 2020 | 27973 | 0.080 |
Why?
|
| Receptors, Immunologic | 1 | 2010 | 139 | 0.080 |
Why?
|
| Neoplasms | 1 | 2024 | 3168 | 0.070 |
Why?
|
| Endocytosis | 1 | 2010 | 184 | 0.070 |
Why?
|
| Glycoproteins | 1 | 2010 | 216 | 0.070 |
Why?
|
| Receptors, Cell Surface | 1 | 2010 | 291 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2013 | 810 | 0.070 |
Why?
|
| Acute Disease | 2 | 2021 | 838 | 0.070 |
Why?
|
| Internship and Residency | 1 | 2016 | 1074 | 0.060 |
Why?
|
| Epithelial Cells | 1 | 2010 | 700 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 3450 | 0.060 |
Why?
|
| Child | 3 | 2023 | 7273 | 0.060 |
Why?
|
| Adolescent | 4 | 2018 | 9550 | 0.050 |
Why?
|
| Aqueous Humor | 1 | 2023 | 21 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2016 | 753 | 0.050 |
Why?
|
| Mass Spectrometry | 1 | 2023 | 187 | 0.050 |
Why?
|
| Leukemic Infiltration | 1 | 2021 | 13 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2021 | 3781 | 0.040 |
Why?
|
| Refraction, Ocular | 1 | 2021 | 11 | 0.040 |
Why?
|
| Rupture, Spontaneous | 1 | 2021 | 42 | 0.040 |
Why?
|
| Descemet Stripping Endothelial Keratoplasty | 1 | 2021 | 18 | 0.040 |
Why?
|
| Ophthalmology | 1 | 2021 | 40 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 2479 | 0.040 |
Why?
|
| Health Policy | 1 | 2021 | 205 | 0.040 |
Why?
|
| Consensus | 1 | 2021 | 366 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 981 | 0.040 |
Why?
|
| Swine | 1 | 2020 | 585 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2019 | 199 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2021 | 297 | 0.030 |
Why?
|
| Paranasal Sinuses | 1 | 2019 | 60 | 0.030 |
Why?
|
| Inflammation | 1 | 2023 | 1049 | 0.030 |
Why?
|
| Comorbidity | 1 | 2021 | 1003 | 0.030 |
Why?
|
| Self Report | 1 | 2019 | 328 | 0.030 |
Why?
|
| Cryotherapy | 1 | 2017 | 30 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2021 | 618 | 0.030 |
Why?
|
| Environment | 1 | 2018 | 230 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2023 | 3044 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2018 | 240 | 0.030 |
Why?
|
| Biomarkers | 1 | 2023 | 1905 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2016 | 174 | 0.030 |
Why?
|
| Facial Injuries | 1 | 2016 | 25 | 0.030 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2017 | 147 | 0.030 |
Why?
|
| Age Distribution | 1 | 2016 | 206 | 0.030 |
Why?
|
| Natamycin | 1 | 2016 | 1 | 0.030 |
Why?
|
| Cross-Linking Reagents | 1 | 2016 | 88 | 0.030 |
Why?
|
| Fluconazole | 1 | 2016 | 11 | 0.030 |
Why?
|
| Retinoschisis | 1 | 2016 | 3 | 0.030 |
Why?
|
| Microscopy, Acoustic | 1 | 2016 | 8 | 0.030 |
Why?
|
| Cysticercus | 1 | 2016 | 2 | 0.030 |
Why?
|
| Amphotericin B | 1 | 2016 | 33 | 0.030 |
Why?
|
| Tacrolimus | 1 | 2017 | 372 | 0.030 |
Why?
|
| Asymptomatic Infections | 1 | 2016 | 20 | 0.030 |
Why?
|
| Lens, Crystalline | 1 | 2016 | 66 | 0.030 |
Why?
|
| Tuberculin Test | 1 | 2015 | 9 | 0.030 |
Why?
|
| Cysts | 1 | 2016 | 99 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2017 | 1014 | 0.030 |
Why?
|
| Antitubercular Agents | 1 | 2015 | 61 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 1447 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2016 | 236 | 0.030 |
Why?
|
| Nasal Mucosa | 1 | 2015 | 193 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 1719 | 0.020 |
Why?
|
| Vero Cells | 1 | 2013 | 98 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2016 | 679 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 2015 | 323 | 0.020 |
Why?
|
| Anti-Infective Agents | 1 | 2013 | 85 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2017 | 987 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2013 | 774 | 0.020 |
Why?
|
| Antibodies, Blocking | 1 | 2010 | 22 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 306 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 2705 | 0.020 |
Why?
|
| Infant | 1 | 2016 | 3156 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2010 | 479 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 1908 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 1786 | 0.020 |
Why?
|
| Virus Replication | 1 | 2010 | 284 | 0.020 |
Why?
|
| Cell Line | 1 | 2013 | 2458 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2010 | 523 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2010 | 710 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 885 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2016 | 4546 | 0.020 |
Why?
|
| Brain | 1 | 2018 | 2337 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 2301 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2010 | 2827 | 0.010 |
Why?
|
| Young Adult | 1 | 2016 | 6922 | 0.010 |
Why?
|
| United States | 1 | 2016 | 7581 | 0.010 |
Why?
|